Role of ABCA 1 and ABCG 1 in Atherogenesis

[1]  G. Franceschini,et al.  Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.

[2]  Michael J. Pencina,et al.  Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.

[3]  A. Kontush,et al.  Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Krieger,et al.  Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. , 2009, Current opinion in lipidology.

[5]  D. Rader,et al.  The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.

[6]  A. Lichtenstein,et al.  Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[7]  G. Watts,et al.  HDL metabolism in context: looking on the bright side , 2008, Current opinion in lipidology.

[8]  Jan Albert Kuivenhoven,et al.  The value of HDL genetics , 2008, Current opinion in lipidology.

[9]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[10]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[11]  Robert A Hegele,et al.  Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency1 Published, JLR Papers in Press, November 8, 2007. , 2008, Journal of Lipid Research.

[12]  K. Drosatos,et al.  Discrete roles of apoA‐I and apoE in the biogenesis of HDL species: Lessons learned from gene transfer studies in different mouse models , 2008, Annals of medicine.

[13]  G. Assmann,et al.  Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study ‡ , 2007, European journal of clinical investigation.

[14]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[15]  H. Brewer,et al.  HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease , 2007, Current cardiology reports.

[16]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[17]  S. Yamashita,et al.  Role of LCAT in HDL remodeling: investigation of LCAT deficiency states Published, JLR Papers in Press, December 20, 2006. , 2007, Journal of Lipid Research.

[18]  B. G. Brown,et al.  Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials , 2006, Current opinion in lipidology.

[19]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[20]  E. Schaefer,et al.  Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction , 2006, Current opinion in lipidology.

[21]  C. Furberg,et al.  Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.

[22]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[23]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[24]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[25]  G. Franceschini,et al.  High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. , 1997, Current opinion in lipidology.

[26]  J. Huttunen,et al.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.

[27]  H. Mabuchi,et al.  Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.

[28]  K. Rye,et al.  High-density lipoproteins, inflammation and oxidative stress. , 2009, Clinical science.

[29]  W. Howard,et al.  Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis , 2008 .